<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31987">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02148718</url>
  </required_header>
  <id_info>
    <org_study_id>W13-984</org_study_id>
    <secondary_id>2013-004781-34</secondary_id>
    <nct_id>NCT02148718</nct_id>
  </id_info>
  <brief_title>Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease</brief_title>
  <acronym>RAPIDA</acronym>
  <official_title>Rapidity of Onset of Response to Adalimumab in Luminal Crohn's Disease (RAPIDA Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pivotal S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratorio Echevarne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rapidity of response to treatments in inflammatory bowel diseases is now considered a field
      of major interest, due to the importance of achieving the highest benefit in the shortest
      possible time, in order to favor a fast backward step to normal life. There are no previous
      studies specifically designed to evaluate the rapidity of response to adalimumab therapy in
      patients with active Crohn's disease. Studies on rapidity of onset of response to adalimumab
      have, on the other hand, been performed in other diseases such as rheumatoid arthritis
      (Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis HERO study, Wolfe et al,
      2006). This trial will assess the clinical responses occurring earlier than in week 1. This
      is an open label, one arm, prospective, multicenter, phase IV clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of patients with clinical response</measure>
    <time_frame>Up to Week 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical response is defined as a decrease of at least 3 points in the Harvey-Bradshaw Index.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with clinical remission</measure>
    <time_frame>Up to Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical remission is defined as Harvey- Bradshaw Index &lt;5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EuroQOL five dimensions (EQ-5D) questionnaire</measure>
    <time_frame>From Week 1 to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>This is used to assess the quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fatigue</measure>
    <time_frame>From Week 1 to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>It is assessed through the Fatigue Impact Scale for Daily Use (D-FIS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in analytic markers of inflammation</measure>
    <time_frame>From Week 1 to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analytic markers include hemogram, erythrocytes sedimentation rate (ESR), C-reactive protein (CRP), fecal calprotectin and coagulation (including fibrinogen).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between Clinical response and remission</measure>
    <time_frame>Up to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Statistical analysis will be performed to evaluate the correlation between a clinical response at day 4 and week 1 with remission at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Bowel Disease Questionnaire-36 (IBDQ36) questionnaire</measure>
    <time_frame>From Week 1 to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>This is used to assess the quality of life.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Moderate to Severe Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adalimumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ADALIMUMAB</intervention_name>
    <description>ADALIMUMAB</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Humira, ABT-D2E7</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Crohn's disease diagnosed within, at least, the previous 4 months.

          -  Patients with active luminal (Harvey-Bradshaw Index ≥8) moderate to- severe Crohn´s
             disease.

          -  No response to a full and adequate course of therapy with a corticosteroid and/or an
             immunosuppressant.

          -  If receiving any of the following treatments, their dose should be stable during the
             periods indicated:

               1. Amino salicylates for, at least, the last 4 weeks

               2. Probiotics for, at least, the last 4 weeks

               3. Analgesics for, at least, the last 4 weeks

               4. Anti-diarrheal' s for, at least, the last 4 weeks

               5. Oral budesonide (maximum dose of 9 mg/day) for, at least, the last 2 weeks

               6. Oral prednisone or equivalent for, at least, the last 2 weeks

               7. Crohn's disease -related antibiotics for, at least, the last 4 weeks

               8. Azathioprine, 6-mercaptopurine or methotrexate for, at least, the last 12 weeks

        Exclusion Criteria:

          -  Previous treatment with any anti-Tumor Necrosis Factor agent.

          -  Surgical bowel resection within the previous 6 months, ostomy, extensive bowel
             resection (&gt; 100 cm), short bowel syndrome, Fistulising Crohn's disease.

          -  Treatment with cyclosporine or tacrolimus within the previous 8 weeks.

          -  Clinically significant cardiac disease including unstable angina, acute myocardial
             infarction within six months from screening, congestive heart failure of worse than
             grade II New York criteria (New York Heart Association Functional Classification).

          -  Subject with an ostomy or ileoanal pouch, proctocolectomy, total colectomy,
             ileostomy, stoma or ileal pouchanal anastomosis (Subjects with a previous ileo-rectal
             anastomosis are not excluded).

          -  Screening laboratory values (according to central laboratory)

          -  Known of hepatitis C (HC) infection.

          -  Serologic evidence of hepatitis B (HB) infection based on the results of testing for
             hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc) and
             hepatitis B surface antibody (anti-HBs) antibodies.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ignacio  Marín, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario Gregorio Marañon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucía  Rodriguez San Pedro</last_name>
    <phone>+34.91.334.40.92 Extn: 3092</phone>
    <email>lucia.rodriguezsanpedro@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rocio   Casado</last_name>
    <phone>+34.91.337.52.85 Extn: 5285</phone>
    <email>rocio.casado@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 125655</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 125655</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 125657</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 125657</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 125659</name>
      <address>
        <city>Barcelono</city>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 125659</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 124197</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 124197</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 125683</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 125683</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 125685</name>
      <address>
        <city>Ferrol</city>
        <zip>15402</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 125685</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 125916</name>
      <address>
        <city>Gerona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 125916</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 125675</name>
      <address>
        <city>Leon</city>
        <zip>24701</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 125675</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 125676</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 125676</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 125686</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 125686</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 125677</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 125677</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 125678</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 125678</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 124200</name>
      <address>
        <city>Malaga</city>
        <zip>13007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 124200</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 125679</name>
      <address>
        <city>Navarra</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 125679</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 124199</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 124196</name>
      <address>
        <city>Sant Joan Despi (Barcelona)</city>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 124196</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 125661</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 125661</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 125681</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 125681</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 125682</name>
      <address>
        <city>Seville</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 125682</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 125656</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 125656</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
    <description>This clinical study is evaluating the drug Humira. Please see prescribing information uses in this link.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 23, 2014</lastchanged_date>
  <firstreceived_date>May 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's Disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
